Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Uppsala Clinical Research Center, Uppsala, Sweden.
JAMA Cardiol. 2018 Dec 1;3(12):1160-1166. doi: 10.1001/jamacardio.2018.3811.
Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes.
To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality.
DESIGN, SETTING, AND PARTICIPANTS: The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated.
Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death.
At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined.
The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43).
In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding.
ClinicalTrials.gov Identifier: NCT00391872.
急性冠状动脉综合征事件发生后一年内的死亡率仍约为 5%。先前的研究评估了与全因或心血管死亡相关的生物标志物,但未评估多种原因导致的死亡。
评估不同的生物标志物是否能提供与全因和病因特异性死亡率相关的信息。
设计、地点和参与者:血小板抑制和患者结局(PLATO)试验于 2006 年 10 月至 2008 年 7 月期间将 18624 例急性冠状动脉综合征患者随机分配至替格瑞洛或氯吡格雷治疗。在这项二级分析生物标志物亚研究中,有 17095 例患者参与。
心肌梗死、心力衰竭、心源性猝死/心律失常、出血、操作、其他血管原因和非血管原因导致的死亡,以及全因死亡。
在基线时,测定胱抑素-C、生长分化因子-15(GDF-15)、高敏 C 反应蛋白、高敏肌钙蛋白 I 和 T 以及 N 末端 B 型利钠肽前体(NT-proBNP)的水平。
患者的中位(四分位间距)年龄为 62.0(54.0-71.0)岁。在 17095 例患者中,782 例(4.6%)在随访期间死亡。使用 Cox 模型对生物标志物与全因和病因特异性死亡率的连续相关性进行建模,并以风险比(HR)表示,比较上下四分位数。对于全因死亡率,NT-proBNP 和 GDF-15 是最强的标志物,校正后的 HR 分别为 2.96(95%CI,2.33-3.76)和 2.65(95%CI,2.17-3.24)。对于心力衰竭导致的死亡,NT-proBNP 与 8 倍风险增加相关,C 反应蛋白、GDF-15 和胱抑素-C 与 3 倍风险增加相关。对于心源性猝死/心律失常,NT-proBNP 与 4 倍风险增加相关,GDF-15 与风险翻倍相关。生长分化因子-15 与其他血管和非血管死亡的关联最强,并且可能与主要出血导致的死亡相关(HR,4.91;95%CI,1.39-17.43)。
在急性冠状动脉综合征患者中,基于 NT-proBNP 和 GDF-15 与心力衰竭导致的死亡以及心律失常和心源性猝死导致的死亡相关,基线水平的 NT-proBNP 和 GDF-15 是与全因死亡相关的强标志物。生长分化因子-15 与其他血管或非血管原因导致的死亡以及可能与出血导致的死亡关联最强。
ClinicalTrials.gov 标识符:NCT00391872。